share_log

Earnings Call Summary | Trinity Biotech(TRIB.US) Q1 2024 Earnings Conference

Earnings Call Summary | Trinity Biotech(TRIB.US) Q1 2024 Earnings Conference

财报电话会议摘要 | 三一生物科技 (TRIB.US) 2024 年第一季度财报会议
富途资讯 ·  05/24 19:51  · 电话会议

The following is a summary of the Trinity Biotech Plc (TRIB) Q1 2024 Earnings Call Transcript:

以下是三一生物技术有限公司(TRIB)2024年第一季度财报电话会议记录的摘要:

Financial Performance:

财务业绩:

  • Trinity Biotech saw nearly 40% quarter-on-quarter growth in Point-of-Care revenues largely attributed to the success of the TrinScreen HIV screening test.

  • Q1 2024 revenues amounted to $14.7 million, a slight decrease from Q1 2023 due to the loss of transplant testing activity at the Buffalo lab.

  • The gross margin improved to 37.6% in light of cost-saving initiatives and is expected to increase with the scaling of production.

  • Opex reduced with an operating loss of $3 million, an improvement from the Q1 2023 loss of $3.9 million.

  • Trinity Biotech的即时医疗收入同比增长了近40%,这在很大程度上归因于TrinScreen艾滋病毒筛查测试的成功。

  • 由于布法罗实验室的移植测试活动中断,2024年第一季度收入为1,470万美元,较2023年第一季度略有下降。

  • 由于采取了节省成本的举措,毛利率提高至37.6%,预计将随着生产规模的扩大而增加。

  • 运营支出减少了300万美元,比2023年第一季度的390万美元亏损有所改善。

Business Progress:

业务进展:

  • Trinity Biotech has been executing key strategic initiatives, such as acquiring new glucose monitoring technology with a view to growth in 2024 and 2025.

  • It applied for ethical approval to initiate a pre-pivotal clinical trial and plans on entering pivotal clinical trials by summer 2025, with EU regulatory approval scheduled for the end of that year.

  • The company signed a strategic collaboration with software companies like PulseAI, launched a new CGM microsite, and appointed Avinash Kale as the director for the CGM program.

  • Trinity Biotech is also making moves to negotiate better pricing from suppliers for raw materials.

  • Trinity Biotech一直在执行关键战略举措,例如收购新的血糖监测技术,以期在2024年和2025年实现增长。

  • 它申请伦理批准,启动一项关键前临床试验,并计划在2025年夏季之前进入关键临床试验,欧盟监管部门的批准定于当年年底进行。

  • 该公司与PulseAI等软件公司签署了战略合作协议,推出了新的CGM微型网站,并任命Avinash Kale为CGM计划的董事。

  • Trinity Biotech也在采取行动,与供应商谈判更优惠的原材料价格。

Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.

提示:欲了解更多详情,请访问投资者关系网站。本文仅供投资者参考,不构成任何投资建议。

译文内容由第三方软件翻译。


以上内容仅用作资讯或教育之目的,不构成与富途相关的任何投资建议。富途竭力但不能保证上述全部内容的真实性、准确性和原创性。
    抢沙发